Funding for this research was provided by:
German Federal Ministry of Health (IIA5-2011-2511AUK320)
Robert Koch Institute (not applicable)
Text and Data Mining valid from 2020-01-10
Received: 9 April 2019
Accepted: 6 November 2019
First Online: 10 January 2020
Ethics approval and consent to participate
: Ethical approval was received from the ethics committee at Charité University Hospital, Berlin, Germany, in May 2011 and with an amendment approved on 19 November 2012 (No EA4/036/11). All participants provided a written informed consent. No personal data allowing identification of study participants was collected. The Federal Commissioner for Data Protection and Freedom of Information approved the study protocol on 29 November 2012 (III-401/008#0035).
: Not applicable.
: Prof. Dr. N. Scherbaum received honoraria for several activities (advisory boards, lectures, manuscripts and educational material) by the factories Abbvie, Hexal, Janssen-Cilag, Lundbeck, MSD, Medice, Mundipharma, Reckitt-Benckiser/Indivior and Sanofi-Aventis. During the last 3 years, he participated in clinical trials financed by the pharmaceutical industry. The other authors declare no competing interests.